ivWatch Chief Nursing Officer Talks Product Support in MD+DI
ivWatch’s Susan Brown recently shared insights on device implementation in the Medical Device and Diagnostic Industry (MD+DI) article, “Training the Trainers to Ensure Customer Satisfaction.” In the piece, she taps on her clinical research experience and training program development for ivWatch to inform readers of best practices during the various stages of the device buying cycle. The article highlights device evaluations, training, implementation, and the need for high-quality medical devices to be accompanied by high-touch servicing models to keep customer satisfaction high. MD+DI is a resource for manufacturers of medical devices and in vitro diagnostic products with a mission to help medtech professionals develop, design, and manufacture products that comply with complex and demanding regulations and evolving market requirements.
Read her article here.
Latest patent grants cover core product technologies
HAMPTON, Va., February 8, 2018 – ivWatch, the only provider of continuous monitoring devices for the early detection of peripheral intravenous (PIV) infiltrations and extravasations, recently had three patent applications granted by the Japanese and Australian Patent Offices expanding the company’s intellectual property portfolio.
“Today’s healthcare marketplace is growing increasingly competitive with the introduction of new devices and technologies, so we must continue to build on our successes in this space by protecting our innovations,” said Gary Warren, president and CEO of ivWatch. “Our philosophy regarding intellectual property is to aggressively protect our proprietary technology to expand our product portfolio and develop licensing opportunities with strategic partners.”
Granted Japanese Patent Application No. 2015-553708 is for a core technology regarding the geometry of ivWatch sensor heads – for both the fiber optic and electronic systems – which has secured ivWatch’s position as a first, and only, technology of its kind in the market. Optimal light angles and distances of the various sensor parts allow the technology to detect infiltrations with high sensitivity to aid healthcare providers in an early diagnosis of these most serious events during intravenous (IV) therapy.
Granted Japanese Patent Application No. 2015-510267 is for a second core technology regarding how an ivWatch sensor head adheres to and is secured on a patient’s skin. These appliances, more commonly known as receptacles, may be independent of the dressings that cover infusion sites during IV therapy or may be integrated with those dressings. The granting of these applications comes just months after ivWatch entered into a licensing and distribution agreement with Terumo Corporation helping to advance patient safety in Japan and on a global scale.
Australian Patent No. 2013316021 is directed to a third core technology for mitigating the effects of tissue blood volume changes. The Australian patent corresponds to U.S. Patent No. 9,326,686, for solving motion issues related to continuous PIV therapy monitoring. The patent is directly related to the ability of the ivWatch Model 400 to reduce the number of “false” notifications helping combat an epidemic of clinicians becoming desensitized to alarms, many of which are false or clinically irrelevant.
These new grants are in addition to the two patents already in ivWatch’s intellectual property portfolio, which also includes numerous utility patent applications. This portfolio gives ivWatch the right to prevent others from making, using or selling our products in the U.S. and major international markets.
There is a rapid demand for breakthrough technology as more healthcare facilities focus on value-based care to lower costs and improve patient safety and satisfaction. IV infiltration and extravasation is a major problem as it can lead to serious medical complications and even amputation. The ivWatch Model 400 continuously monitors a patient’s PIV for evidence of infiltrations and extravasations, which occur when medication or fluid leaks into the surrounding tissue. Early detection of those failures via ivWatch biosensor technology helps to minimize injuries associated with this common complication of IV therapy.
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLC. https://www.ivWatch.com/
MEDIA CONTACT: Amara Betoney, email@example.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949
The ivWatch team is returning to the Society of Critical Care Medicine’s (SCCM) Critical Care Congress on February 25-27, 2018 for the third consecutive year. The Society’s Congress embarks on their 47th annual event and remains the largest critical care event bringing together members of the multi-professional, multidisciplinary critical care field.
ivWatch representatives will be at booth 224 in the exhibit hall educating attendees about the latest technology advancements in peripheral IV therapy care. ivWatch shares in the Society’s mission of securing the highest quality care for all critically ill and injured patients.
In previous years, we’ve met with several pediatric and neonatal intensive care unit teams as well as those in the operating room. Whether you are a department or patient safety director, sit on a value-analysis committee, or simply interested in learning about evidence-based ways to improve patient care, we invite you to stop by or reach out. We’ll have ongoing demonstrations of the ivWatch Model 400, the only medical device and biosensor technology that continuously monitors the IV site for the early detection of IV infiltrations to help improve patient safety and minimize patient harm.
We look forward to collaborating with critical care experts and internationally renowned faculty in a few weeks.
HAMPTON, Va.., February 6, 2018 – ivWatch, LLC has been awarded a group purchasing agreement as a Breakthrough Technology with Premier. Effective Feb.1, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the ivWatch Model 400, a continuous monitoring device for the early detection of peripheral IV (PIV) infiltrations.
“We are thrilled to be recognized by Premier as a Breakthrough Technology which accelerates the standard GPO process and enables us to educate more organizations about our technology offering a new standard of care for PIVs,” said Scott Hensley, vice president of sales and business development at ivWatch. “This recognition is a testament to the need for a technology solution in hospitals for continuous IV monitoring for early detection of IV infiltrations and extravasations.”
This relationship enables Premier members to implement continuous monitoring of a patient’s PIV for evidence of infiltrations to improve patient outcomes. Intravenous therapy is a routine part of treatment for nearly 80 percent of patients in the U.S., yet more than 20 percent of these IVs may fail due to infiltration, risking both a serious drug delivery error and tissue damage. The ivWatch sensor technology is a solution to aid the clinician in early detection of this most serious event.
Premier is a leading healthcare improvement company, uniting an alliance of approximately 3,900 U.S. hospitals and 150,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost.
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLC. https://www.ivwatch.com/
ivWatch President and CEO Discusses Thoughts on Human Factors and Technology Acceptance in Healthcare
ivWatch’s Gary Warren penned an exclusive piece for MedTech Intelligence titled, “.” In the column, he discusses how medical device human factor engineering must account for all groups within the Diffusion of Innovation curve. MedTech Intelligence is an industry-specific website that aids in the advancement and progress of the global medical device and diagnostic industry.
Read his column here.
ivWatch Chief Nursing Officer on WTKR’s Coast Live
ivWatch’s Susan Brown educated viewers about patient empowerment and IV care and risks. The morning show segment included information about how the ivWatch device detects IV infiltrations early and ways current and future hospital patients can prepare for this common but often overlooked procedure.
View the full segment here.